Faropenem
Based on 2 publication(s) in Google Scholar
Faropenem is a potent and orally active beta-lactam antibiotic. Faropenem demonstrates broad-spectrum in vitro antimicrobial activity against many gram-positive and -negative aerobes and anaerobes. Faropenem is resistant to hydrolysis by nearly all beta-lactamases, including extended-spectrum beta-lactamases and AmpC beta-lactamases. Faropenem is developed as an oral proagent, faropenem medoxomil, for the research of respiratory tract infections.
For research use only. We do not sell to patients.
- CAS No.: 106560-14-9
- Formula: C12H15NO5S
- Molecular Weight:285.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Faropenem
MoreAll Antibiotic Isoforms
More
Biological Activity
|
β-lactam |
Faropenem is not active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, Pseudomonas aeruginosa or Stenotrophomonas maltophilia[1].Faropenem is against all isolates of B. anthracis. The MIC values ranged from ≤0.06 to >64 μg/liter, and the MIC90 value is 0.5 μg/ml. The MIC90 value for Faropenem is lower than that observed for other β-lactams, such as Meropenem, Amoxicillin-clavulanate, and Penicillin, for which the MIC90 values are 4 μg/ml, 4 μg/ml, and 8 μg/ml, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 106560-14-9
-
Molecular Weight 285.32
-
Formula C12H15NO5S
-
SMILES
O=C(C(N12)=C([C@@H]3OCCC3)S[C@]2([H])[C@@H]([C@H](O)C)C1=O)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int J Antimicrob Agents
In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex. [Abstract]2022 Nov-Dec;60(5-6):106669. PMID: 36064079 -
J Glob Antimicrob Resist
Susceptibility of multidrug-resistant Escherichia coli and Klebsiella pneumoniae to oral antibiotics in Australia. [Abstract]2025 Aug 8:44:435-441. PMID: 40784378
Purity & Documentation
References
[1]. Kristen N Schurek, et al. Faropenem: review of a new oral penem. Expert Rev Anti Infect Ther. 2007 Apr;5(2):185-98. [Content Brief]
[2]. Stanley C Gill, et al. Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. Antimicrob Agents Chemother. 2010 May;54(5):1678-83. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz